A randomized, double‐blind, placebo‐controlled trial of pridopidine in Huntington's disease
Identifieur interne : 001030 ( Main/Exploration ); précédent : 001029; suivant : 001031A randomized, double‐blind, placebo‐controlled trial of pridopidine in Huntington's disease
Auteurs :Source :
- Movement Disorders [ 0885-3185 ] ; 2013-09.
Abstract
We examined the effects of 3 dosages of pridopidine, a dopamine‐stabilizing compound, on motor function and other features of Huntington's disease, with additional evaluation of its safety and tolerability. This was a randomized, double‐blind, placebo‐controlled trial in outpatient neurology clinics at 27 sites in the United States and Canada. Two hundred twenty‐seven subjects enrolled from October 24, 2009, to May 10, 2010. The intervention was pridopidine, either 20 (n=56), 45 (n=55), or 90 (n=58) mg daily for 12 weeks or matching placebo (n=58). The primary outcome measure was the change from baseline to week 12 in the Modified Motor Score, a subset of the Unified Huntington's Disease Rating Scale Total Motor Score. Measures of safety and tolerability included adverse events and trial completion on the assigned dosage. After 12 weeks, the treatment effect (relative to placebo, where negative values indicate improvement) of pridopidine 90 mg/day on the Modified Motor Score was −1.2 points (95% confidence interval [CI], −2.5 to 0.1 points; P = .08). The effect on the Total Motor Score was −2.8 points (95% CI, −5.4 to −0.1 points; nominal P = .04). No significant effects were seen in secondary outcome measures with any of the active dosages. Pridopidine was generally well tolerated. Although the primary analysis did not demonstrate a statistically significant treatment effect, the overall results suggest that pridopidine may improve motor function in Huntington's disease. The 90 mg/day dosage appears worthy of further study. Pridopidine was well tolerated. © 2013 International Parkinson and Movement Disorder Society
Url:
DOI: 10.1002/mds.25362
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001C48
- to stream Istex, to step Curation: 001C48
- to stream Istex, to step Checkpoint: 000148
- to stream Main, to step Merge: 001042
- to stream Main, to step Curation: 001030
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A randomized, double‐blind, placebo‐controlled trial of pridopidine in Huntington's disease</title></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0C6BD93933EC4F6C6EB2B8246DB6E4F0620342A0</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1002/mds.25362</idno><idno type="url">https://api-v5.istex.fr/document/0C6BD93933EC4F6C6EB2B8246DB6E4F0620342A0/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001C48</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001C48</idno><idno type="wicri:Area/Istex/Curation">001C48</idno><idno type="wicri:Area/Istex/Checkpoint">000148</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000148</idno><idno type="wicri:Area/Main/Merge">001042</idno><idno type="wicri:Area/Main/Curation">001030</idno><idno type="wicri:Area/Main/Exploration">001030</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A randomized, double‐blind, placebo‐controlled trial of pridopidine in Huntington's disease</title></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><date type="published" when="2013-09">2013-09</date><biblScope unit="volume">28</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1407">1407</biblScope><biblScope unit="page" to="1415">1415</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">0C6BD93933EC4F6C6EB2B8246DB6E4F0620342A0</idno><idno type="DOI">10.1002/mds.25362</idno><idno type="ArticleID">MDS25362</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">We examined the effects of 3 dosages of pridopidine, a dopamine‐stabilizing compound, on motor function and other features of Huntington's disease, with additional evaluation of its safety and tolerability. This was a randomized, double‐blind, placebo‐controlled trial in outpatient neurology clinics at 27 sites in the United States and Canada. Two hundred twenty‐seven subjects enrolled from October 24, 2009, to May 10, 2010. The intervention was pridopidine, either 20 (n=56), 45 (n=55), or 90 (n=58) mg daily for 12 weeks or matching placebo (n=58). The primary outcome measure was the change from baseline to week 12 in the Modified Motor Score, a subset of the Unified Huntington's Disease Rating Scale Total Motor Score. Measures of safety and tolerability included adverse events and trial completion on the assigned dosage. After 12 weeks, the treatment effect (relative to placebo, where negative values indicate improvement) of pridopidine 90 mg/day on the Modified Motor Score was −1.2 points (95% confidence interval [CI], −2.5 to 0.1 points; P = .08). The effect on the Total Motor Score was −2.8 points (95% CI, −5.4 to −0.1 points; nominal P = .04). No significant effects were seen in secondary outcome measures with any of the active dosages. Pridopidine was generally well tolerated. Although the primary analysis did not demonstrate a statistically significant treatment effect, the overall results suggest that pridopidine may improve motor function in Huntington's disease. The 90 mg/day dosage appears worthy of further study. Pridopidine was well tolerated. © 2013 International Parkinson and Movement Disorder Society</div></front></TEI><affiliations><list></list><tree></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001030 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001030 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:0C6BD93933EC4F6C6EB2B8246DB6E4F0620342A0
|texte= A randomized, double‐blind, placebo‐controlled trial of pridopidine in Huntington's disease
}}
| This area was generated with Dilib version V0.6.29. |  |